Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Net Margin (2022 - 2026)

Indivior Pharmaceuticals has reported Net Margin over the past 5 years, most recently at 28.08% for Q1 2026.

  • For Q1 2026, Net Margin rose 1003.0% year-over-year to 28.08%; the TTM value through Mar 2026 reached 19.44%, up 2004.0%, while the annual FY2025 figure was 16.95%, 1636.0% up from the prior year.
  • Net Margin for Q1 2026 was 28.08% at Indivior Pharmaceuticals, down from 28.49% in the prior quarter.
  • Over five years, Net Margin peaked at 30.8% in Q2 2023 and troughed at 136.51% in Q4 2022.
  • A 5-year average of 1.19% and a median of 19.94% in 2024 define the central range for Net Margin.
  • On a YoY basis, Net Margin climbed as much as 15972bps in 2023 and fell as far as -11264bps in 2023.
  • Year by year, Net Margin stood at 136.51% in 2022, then soared by 117bps to 23.21% in 2023, then plummeted by -70bps to 7.05% in 2024, then surged by 304bps to 28.49% in 2025, then decreased by -1bps to 28.08% in 2026.
  • Business Quant data shows Net Margin for INDV at 28.08% in Q1 2026, 28.49% in Q4 2025, and 13.38% in Q3 2025.